Popular terms


Autoimmune topics
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents


Autoimmune patents

This page is updated frequently with new Autoimmune-related patent applications. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune RSS RSS

Date/App# patent app List of recent Autoimmune-related patents
 Therapeutic apoptotic cell preparations,  producing same and uses thereof patent thumbnailnew patent Therapeutic apoptotic cell preparations, producing same and uses thereof
The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (gvhd) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis..
Enlivex Therapeutics Ltd.

 Heterodimer binding proteins and uses thereof patent thumbnailnew patent Heterodimer binding proteins and uses thereof
The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin ch1 region and an immunoglobulin light chain constant region (cl). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor).
Emergent Product Development Seattle Llc

 Human anti-human epidemic growth factor receptor antibody and encoding gene and application thereof patent thumbnailnew patent Human anti-human epidemic growth factor receptor antibody and encoding gene and application thereof
The present invention provides human anti-human epidermal growth factor receptor (egfr) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human egfr gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein.
Shanghai Serum Biotechnology Co., Ltd.

 Therapeutic cd47 antibodies patent thumbnailnew patent Therapeutic cd47 antibodies
Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to cd47 of multiple mammalian species, block the binding of sirpalpha and tsp1 to cd47, promote phagocytosis of susceptible cancer cells, and reverse tsp1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing.
Vasculox Inc.

 Fibronectin based scaffold domain proteins that bind il-23 patent thumbnailnew patent Fibronectin based scaffold domain proteins that bind il-23
The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (il-23), specifically the p19 subunit of il-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases.
Bristol-myers Squibb Company

 Therapeutically active oxazoline derivatives patent thumbnailnew patent Therapeutically active oxazoline derivatives
Compounds of formula (i) i.e. Monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection..
Katholieke Universiteit Leuven, K.u.leuven R&d

 Substituted tricyclic benzimidazoles as kinase inhibitors patent thumbnailnew patent Substituted tricyclic benzimidazoles as kinase inhibitors
Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (i) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit cdk8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases.
Selvita Sa

 Tropomyosin-related kinase (trk) inhibitors patent thumbnailnew patent Tropomyosin-related kinase (trk) inhibitors
Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

 Novel compound useful for the treatment of degenerative and inflammatory diseases patent thumbnailnew patent Novel compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
Galapagos Nv

 Inhibitors of histone methyltransferase g9a patent thumbnailnew patent Inhibitors of histone methyltransferase g9a
Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase g9a.. .
Abbvie Inc.

new patent


Y is oh, oalkyl, nr2r3. The compounds are useful e.g.

new patent

Mesenchymal stem cells and uses therefor

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl

new patent

Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor

This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, copd). The method comprises administering a pi3k delta inhibitor or a dual pi3k delta-gamma inhibitor and a pde4 inhibitor.
Rhizen Pharmaceuticals Sa


Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory t cell stability and function via a neuropilin-1:semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory t cell (treg)-restricted neuropilin-1 (nrp 1) interacts with the cell surface ligand semaphorin-4a (sema4a) (e.g., on conventional t cells (tconv), conventional dendritic cells (cdcs), and/or plasmacytoid dendritic cells (pdcs)) to potentiate reg function and enhance their survival at inflammatory sites..
St. Jude Children's Research Hospital, Inc.


Il-21 antibodies

The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human il-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of il-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.. .
Eli Lilly And Company


Pyrazolo[4,3-d]pyrimidines as kinase inhibitors

The present invention relates to novel compounds of formula (i) that are capable of inhibiting one or more kinases, especially syk (spleen tyrosine kinase), lrrk2 (leucine-rich repeat kinase 2) and/or mylk (myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.
Origenis Gmbh


Rorgamma modulators

Described are rory modulators of the formula (i), and n-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein r1, r2, r3, r4, r5, r6, ra, x, y, l, g, z, the bond denoted by “q”, the ring system denoted by “a” and the ring system denoted by “b” are defined herein. Also provided are pharmaceutical compositions comprising the same.
Exelixis, Inc.


Pyrazole amide derivative

The present invention relates to a novel compound having a function of inhibiting rorγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases..
Teijin Pharma Limited


Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


Igm therapy in prevention of onset, progression, and recurrence of autoimmune type 1 diabetes

The therapeutic potential of polyclonal serum naturally occurring igm (nigm) administration in preventing the onset and progression of autoimmune type 1 diabetes and in promoting graft survival following islet allotransplantation has been investigated. Nigm therapy prevents both, onset and progression of diabetes and promotes islet graft survival..
University Of Virginia Patent Foundation


Immunomodulating compositions and uses therefor

The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses.


Recruitment of mensenchymal cells using controlled release systems

The present invention provides microparticles that deliver in vivo predictable release profiles of at least one chemokine to create a biomimetic chemokine concentration gradient that induces the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle.
University Of Pittsburgh-of The Commonwealth Syste System Of Higher Education


Method of treating skin disorders

A skin care product includes a compound of formula i, ia, or ib (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen.
Rcp Development, Inc.


Method for evaluating and comparing immunorepertoires

Disclosed is a method for amplifying rna and/or dna from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.. .


Anti-mcam antibodies and associated methods of use

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions and pharmaceutical formulations, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer..
Prothena Biosciences Limited


Long acting trial receptor agonists for treatment of autoimmune diseases

Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory t cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a trail-conjugate. Preferably, the trail-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the trail-conjugate.
Theraly Pharmaceuticals Inc.


Novel kinase inhibitors

The present invention relates to novel compounds of formula (i) that are capable of inhibiting one or more kinases, especially syk (spleen tyrosine kinase), lrrk2 (leucine-rich repeat kinase 2) and/or mylk (myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.
Origenis Gmbh


Acylpiperazines as inhibitors of transglutaminase and their use in medicine

The present invention relates to novel compounds of formula i capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g.
Aston University


Nanocarriers and their processing for diagnostics and therapeutics

The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis..
Rhode Island Hospital


Human toll-like receptor inhibitors and methods of use thereof

Provided herein are human toll-like receptor (tlr)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The tlr inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of tlr7, tlr8 and tlr9..
Dynavax Technologies Corporation


Icam-1 antibody and use thereof

Disclosed are a monoclonal antibody targeting domain 2 of icam-1 protein and a composition comprising the monoclonal antibody for treating or preventing t cell-mediated immune disease. The antibody of the present application induces antigen-specific t cell tolerance through the regulation of dendritic cell differentiation, and therefore, can be effectively used to treat or prevent autoimmune disease, organ or tissue transplant rejection, and graft-versus-host-disease..
Snu R&db Foundation


Anti-cd19 antibodies

The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Immunomedics, Inc.


Antibody and methods for selective inhibition of t-cell responses

The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ tcr antibodies and antibody fragments. Anti-αβ tcr antibodies are antibodies which bind to a αβ tcr.
Tolera Therapeutics, Inc.


Virus-containing formulation and use thereof

The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying.
Transgene Sa


Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis

Nanoparticles to treat autoimmune diseases and hiv infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (mhc) class i antigen e (hla-e) linked to a peptide, and wherein the hla-e-peptide complex is linked to the surface of the nanoparticle.
Dana-farber Cancer Institute, Inc.


Methods and compositions for modifying the immune response

The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins..
University Health Network


Use of vitamin d glycosides and sulfates for treatment of disease

Methods of treating vitamin d-sensitive diseases without inducing severe forms of hypercalcemia. The methods comprise administering biologically inert vitamin d prodrugs.


Diagnosis and treatment of autoantibody-mediated heart disease

Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of igg4 antibodies to cardiac autoantigens.. .


Gp2 isoforms and their use in autoantibody capture

The invention relates to a method for binding or capturing autoantibodies directed to various glycoprotein 2 (gp2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of gp2.
Ga Generic Assays Gmbh


Diagnostic detecting an autoimmune disease and related subject-matter

The present invention relates to a polypeptide or protein for use in a method of diagnosis or treatment of an autoimmune disease in a subject, characterized in that said polypeptide or protein comprises one or more epitopes derived from the protein dppx. Further, the invention relates to a nucleic acid or vector encoding such polypeptide, to a cell comprising such a vector, to an in vitro diagnostic method and test kit involving such polypeptide, to a pharmaceutical composition comprising such polypeptide, to a medical device coated with such polypeptide or pharmaceutical composition and to methods for treating an autoimmune disease in a subject..
Institut D'investigaciones BiomÈdiques August Pii Sunyer


Immunoglobuljin-binding human mycoplasma antigens and methods of use thereof

Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (mgus), which methods include administering an agent effective to treat a mycoplasma infection. The invention also relates to a new class of antigen, mg281 protein {also referenced as protein m), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins.
The Scripps Research Institute


Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i) or (ii), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject.
Beth Israel Deaconess Medical Center, Inc.


Apoptosis signal-regulating kinase inhibitors

Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases..


Benzimidazole derivatives as pi3 kinase inhibitors

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Glaxosmithkline Llc


Tert-butyl n-[2-ethyl]-l-alaninate or a salt, hydrate or solvate thereof

The present invention provides a compound which is: tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5-difluorophenyl}ethyl)-l-alaninate or a salt, hydrate or solvate thereof. The present invention also provides a pharmaceutical composition comprising the compound together with one or more pharmaceutically acceptable carriers and/or excipients.
Chroma Therapeutics Ltd.


Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-jun amino terminal kinase, jnk inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to jnk signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders.. .
Xigen Inflammation Ltd.


Immune privileged and modulatory progenitor cells

Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed hucpvcs derived from the perivascular region of human umbilical cord.


Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Alliant Techsystems Inc.

Popular terms: [SEARCH]

Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents


This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.



459775 - 0 - 111